[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].

Neznamov GG, Dorofeeva OA, Metlina MV, Syunyakov TS, Minaev SV, Ivashkina NY, Martyanov VA, Seredenin SB

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2019Cited by 1 (Europe PMC)

PMID31626171DOI10.17116/jnevro201911908153PepBankPUB-31626171

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with generalized anxiety disorder, the effective GB‑115 dose was determined as 6 mg per day.
In plain wordsIn patients with generalized anxiety disorder, the study identified 6 mg per day as the effective GB‑115 dose.
Peptide
GB-115
Outcome
Not applicableEffective dose
Study
n = 31
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
6 mg per day · oral · 21 daysAs given in this study (human).
Source sentences
Summary
The effective dose of GB-115 was determined at 6 mg per day.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years.
Summary · context
The duration of treatment was 21 days.
Report a problemFND-3162617101
02HumanNon-randomized trialEfficacy outcome
In patients with generalized anxiety disorder, GB‑115 showed rapid anxiolytic action with stimulating properties and benefits for sleep and autonomic symptoms.
In plain wordsIn patients with generalized anxiety disorder, GB‑115 showed rapid anxiety relief with stimulation and benefits for sleep and autonomic symptoms.
Peptide
GB-115
Outcome
Direction not reportedAnxiolytic effect with stimulating properties and symptom benefits
Study
n = 31
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · oral · 21 daysAs given in this study (human).
Source sentences
Summary
Drug action is characterized by fast onset of anxiolytic effect with stimulating properties and beneficial effect on sleep disturbances and autonomic symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years.
Summary · context
The duration of treatment was 21 days.
Report a problemFND-3162617102
03HumanNon-randomized trialEfficacy outcome
In patients with generalized anxiety disorder, GB‑115 treatment was associated with favorable attention, reaction time, and overall performance changes.
In plain wordsIn patients with generalized anxiety disorder, GB‑115 treatment was linked to favorable attention, reaction time, and overall performance changes.
Peptide
GB-115
Outcome
Direction not reportedCognitive performance
Study
n = 31
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · oral · 21 daysAs given in this study (human).
Source sentences
Summary
GB-115 treatment was associated with favorable changes in attention parameters, reaction time and overall performance.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years.
Summary · context
The duration of treatment was 21 days.
Report a problemFND-3162617103
04HumanNon-randomized trialSafety outcome
In patients with generalized anxiety disorder, GB‑115 did not induce initial overactivation.
In plain wordsIn patients with generalized anxiety disorder, GB‑115 did not induce initial overactivation.
Peptide
GB-115
Outcome
Not applicableInitial overactivation
Study
n = 31
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated · oral · 21 daysAs given in this study (human).
Source sentences
Summary
In contrast to first-line drugs for GAD treatment (SSRIs and SNRIs), GB-115 does not induce initial overactivation, anxiety and sleep disturbances.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years.
Summary · context
The duration of treatment was 21 days.
Report a problemFND-3162617104
05HumanNon-randomized trialSafety outcome
In patients with generalized anxiety disorder, GB‑115 was described as safe and well tolerated without numerical safety data.
In plain wordsIn patients with generalized anxiety disorder, the abstract described GB‑115 as safe and well tolerated.
Peptide
GB-115
Outcome
Direction not reportedSafety and tolerability
Study
n = 31
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · oral · 21 daysAs given in this study (human).
Source sentences
Summary
GB-115 is safe and has a good tolerability.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years.
Summary · context
The duration of treatment was 21 days.
Report a problemFND-3162617105
06HumanNon-randomized trialSafety outcome
In patients with generalized anxiety disorder, GB‑115 did not induce initial anxiety.
In plain wordsIn patients with generalized anxiety disorder, GB‑115 did not induce initial anxiety.
Peptide
GB-115
Outcome
Not applicableInitial anxiety
Study
n = 31
Outcome group
Adverse events · Mental health and mood
Studied dose
Dose not stated · oral · 21 daysAs given in this study (human).
Source sentences
Summary
In contrast to first-line drugs for GAD treatment (SSRIs and SNRIs), GB-115 does not induce initial overactivation, anxiety and sleep disturbances.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years.
Summary · context
The duration of treatment was 21 days.
Report a problemFND-3162617106
07HumanNon-randomized trialSafety outcome
In patients with generalized anxiety disorder, GB‑115 did not induce sleep disturbances.
In plain wordsIn patients with generalized anxiety disorder, GB‑115 did not induce sleep disturbances.
Peptide
GB-115
Outcome
Not applicableSleep disturbances
Study
n = 31
Outcome group
Adverse events · Sleep
Studied dose
Dose not stated · oral · 21 daysAs given in this study (human).
Source sentences
Summary
In contrast to first-line drugs for GAD treatment (SSRIs and SNRIs), GB-115 does not induce initial overactivation, anxiety and sleep disturbances.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years.
Summary · context
The duration of treatment was 21 days.
Report a problemFND-3162617107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.